Mostrar el registro sencillo del ítem
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
dc.rights.license | open | en_US |
dc.contributor.author | JOHNSON-ANSAH, Hyacinthe | |
dc.contributor.author | MANEGLIER, Benjamin | |
dc.contributor.author | HUGUET, Francoise | |
dc.contributor.author | LEGROS, Laurence | |
dc.contributor.author | ESCOFFRE-BARBE, Martine | |
dc.contributor.author | GARDEMBAS, Martine | |
dc.contributor.author | CONY-MAKHOUL, Pascale | |
dc.contributor.author | COITEUX, Valerie | |
dc.contributor.author | SUTTON, Laurent | |
dc.contributor.author | ABARAH, Wajed | |
dc.contributor.author | POUATY, Camille | |
dc.contributor.author | PIGNON, Jean-Michel | |
dc.contributor.author | CHOUFI, Bachra | |
dc.contributor.author | VISANICA, Sorin | |
dc.contributor.author | DEAU, Benedicte | |
dc.contributor.author | MORISSET, Laure | |
dc.contributor.author | CAYSSIALS, Emilie | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | MOLIMARD, Mathieu | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | BOUCHET, Stephane | |
dc.contributor.author | MAHON, Francois-Xavier | |
dc.contributor.author | NICOLINI, Franck | |
dc.contributor.author | AEGERTER, Philippe | |
dc.contributor.author | CAYUELA, Jean-Michel | |
dc.contributor.author | DELORD, Marc | |
dc.contributor.author | BRUZZONI-GIOVANELLI, Heriberto | |
dc.contributor.author | ROUSSELOT, Philippe | |
dc.date.accessioned | 2022-10-28T06:59:06Z | |
dc.date.available | 2022-10-28T06:59:06Z | |
dc.date.issued | 2022-08-12 | |
dc.identifier.issn | 1999-4923 (Print) 1999-4923 (Linking) | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/170131 | |
dc.description.abstractEn | The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug's efficacy or tolerance. We decided to conduct a prospective randomized trial (OPTIM-imatinib trial) to assess the value of TDM in patients with chronic phase chronic myelogenous treated with imatinib as first-line therapy (NCT02896842). Eligible patients started imatinib at 400 mg daily, followed by imatinib [C]min assessment. Patients considered underdosed ([C]min < 1000 ng/mL) were randomized in a dose-increase strategy aiming to reach the threshold of 1000 ng/mL (TDM arm) versus standard imatinib management (control arm). Patients with [C]min levels >/= 1000 ng/mL were treated following current European Leukemia Net recommendations (observational arm). The primary endpoint was the rate of major molecular response (MMR, BCR | |
dc.language.iso | EN | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject.en | Imatinib | |
dc.subject.en | Therapeutic drug monitoring | |
dc.subject.en | Chronic myelogenous leukemia | |
dc.title.en | Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.3390/pharmaceutics14081676 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 3601530 | en_US |
bordeaux.journal | Pharmaceutics | en_US |
bordeaux.page | 1676 | en_US |
bordeaux.volume | 14 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 8 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | AHEAD_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-03832869 | |
hal.version | 1 | |
hal.date.transferred | 2022-10-28T06:59:11Z | |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.date=2022-08-12&rft.volume=14&rft.issue=8&rft.spage=1676&rft.epage=1676&rft.eissn=1999-4923%20(Print)%201999-4923%20(Linking)&rft.issn=1999-4923%20(Print)%201999-4923%20(Linking)&rft.au=JOHNSON-ANSAH,%20Hyacinthe&MANEGLIER,%20Benjamin&HUGUET,%20Francoise&LEGROS,%20Laurence&ESCOFFRE-BARBE,%20Martine&rft.genre=article |